Introduction {#cesec10}
============

Medulloblastoma is an embryonal brain tumour of the cerebellum, with an annual age-adjusted incidence ranging from 2·0 cases per 1 000 000 to 5·8 cases per 1 000 000 worldwide.[@bib1] The cause of medulloblastoma is largely unclear and most cases are presumed to arise sporadically.[@bib2] Medulloblastoma has been observed in conjunction with several rare disorders, including Gorlin syndrome (associated with mutations in *SUFU* and *PTCH1*),[@bib3], [@bib4] Li-Fraumeni syndrome (*TP53*),[@bib5] *APC*-associated polyposis conditions,[@bib6] and Fanconi anaemia (*BRCA2*).[@bib7] However, the full spectrum and prevalence of genetic predisposition involving damaging germline mutations in paediatric-onset and adult-onset cancer predisposition genes[@bib8] remains unknown. Following the recognition[@bib9] of four consensus molecular subgroups (WNT \[MB~WNT~\], SHH \[MB~SHH~\], group 3 \[MB~Group3~\], and group 4 \[MB~Group4~\]) with distinct demographics and clinical outcomes,[@bib10] patients with germline *TP53, SUFU*, and *PTCH1* mutations have been reported to be predisposed to develop MB~SHH~.[@bib11], [@bib12] Although several case studies have reported medulloblastomas arising in patients with Fanconi anaemia, whether these predispose to specific medulloblastoma subgroups, and whether heterozygous germline mutations[@bib13] also confer an increased risk of developing medulloblastoma, remain unknown. Furthermore, whether and to what extent the presence of predisposing germline mutations affects clinical outcome is unclear. A comprehensive study[@bib14] of damaging germline mutations in cancer predisposition genes across a diverse set of paediatric cancers identified variants likely to predispose to the disease in three (8%) of 37 patients with medulloblastoma---a cohort size that is too small to allow these issues to be thoroughly addressed. Owing to these uncertainties, and since knowledge about germline mutations can be useful for clinical practice,[@bib8] assessment of larger patient series is crucial for the identification of consensus medulloblastoma predisposition genes to estimate the contribution of genetic predisposition towards consensus molecular subgroups, and to investigate whether affected patients have distinct clinical outcomes. A comprehensive understanding of molecular alterations in affected patients would further help in the development of clinical screening guidelines for genetic risk assessment in paediatric patients.

In this study, we provide a comprehensive description of genetic risk factors across 1022 patients with medulloblastoma based on a retrospective discovery cohort and validation in a prospective clinical cohort. We validated a set of six consensus medulloblastoma predisposition genes, and report associations between germline mutations and patient characteristics, molecular subgroups, somatic mutation landscapes, and clinical outcomes.

Methods {#cesec20}
=======

Study design and participants {#cesec30}
-----------------------------

This series was based on 1022 patients with medulloblastoma (491 published[@bib12], [@bib15], [@bib16], [@bib17], [@bib18] and 531 as yet unpublished cases), and comprised whole-genome and whole-exome sequencing data for the whole set of donor samples available to use from the International Cancer Genome Consortium (ICGC), the Medulloblastoma Advanced Genomics International Consortium (MAGIC), and the CEFALO series,[@bib19] and from four prospective clinical studies (SJMB03 \[[NCT00085202](ctgov:NCT00085202){#interrefs10}\], SJMB12 \[[NCT01878617](ctgov:NCT01878617){#interrefs20}\], SJYC07 \[[NCT00602667](ctgov:NCT00602667){#interrefs30}\], and I-HIT-MED \[[NCT02417324](ctgov:NCT02417324){#interrefs40}\]). We obtained biological samples from all patients, who all provided written informed consent, in accordance with institutional review board guidelines.

Research in context**Evidence before this study**We searched PubMed for journal articles and case reports from Aug 1, 1925, up to Dec 31, 2017, with the terms "medulloblastoma" and "germline OR familial OR syndrome OR heritable OR susceptibility", and the names of 110 genes in which germline mutations confer increased risk of paediatric and adult cancers. About 100 studies identified damaging germline mutations in nearly 20 genes, primarily in *APC, BRCA2, PTCH1, SUFU*, and *TP53*. Several studies were based on case reports and small-scale series. Additionally, which patients would benefit from genetic counselling in the context of molecular subgrouping---nowadays routinely applied in clinical trials and implemented into the revised WHO classification of CNS tumours in 2016---and whether genetic predisposition can be recognised based on familial patterns were unclear. Additionally, several paediatric cancer centres have implemented routine multigene panel analysis and whole-exome analysis of medulloblastomas; however, these centres encounter several germline mutations with uncertain clinical significance. No study has previously aimed to define a consensus set of medulloblastoma predisposition genes or has investigated under which circumstances genetic counselling and testing should be offered to patients with medulloblastoma.**Added value of this study**This study is based on an international cohort of 1022 patients with medulloblastoma, and includes detailed information about medulloblastoma subgroups (WNT \[MB~WNT~\], SHH \[MB~SHH~\], group 3 \[MB~Group3~\], and group 4 \[MB~Group4~\]), somatic mutation landscapes, and clinical outcomes. We defined and characterised six consensus, clinically relevant medulloblastoma predisposition genes on the basis of rare variant burden analysis *(APC, BRCA2, PALB2, PTCH1, SUFU,* and *TP53*). Half of all patients with damaging germline mutations were not recognised based on familial history of cancer; however, these patients exhibited distinct phenotypes with respect to age at diagnosis, molecular subgroups, somatic mutation patterns, and clinical outcomes. Paediatric patients with heterozygous germline *PALB2* mutations exhibited mutational signatures consistent with homologous recombination repair deficiency and all patients with medulloblastoma showed no signs characteristic of Fanconi anaemia. About one in five patients in the MB~SHH~ subgroup developed medulloblastoma in the context of a genetic predisposition, underscoring the need for a dedicated genetic screening programme and surveillance programme in this patient group. Patients in the MB~WNT~ subgroup had an intermediate risk of damaging germline mutations, and clear genotype--phenotype associations that guide the ordering of genetic tests. Damaging germline mutations in known cancer predisposition genes were rare in paediatric patients in the MB~Group3~ and MB~Group4~ subgroups, which indicates conservative ordering of genetic tests in these groups. We propose clinical guidelines for genetic screening in medulloblastoma based on routinely acquired clinical and molecular tumour phenotypes.**Implications of all the available evidence**A significant prevalence of clinically important germline mutations in two of four molecular subgroups reveals that genetic counselling and testing should be established as a standard-of-care procedure in the management of patients with medulloblastoma. The proposed testing algorithm has been implemented in the International Society of Paediatric Oncology clinical trial PNET 5 MB ([NCT02066220](ctgov:NCT02066220){#interrefs50}), which is currently recruiting patients.

Patient accrual for our retrospective cohort was done from 2003 until 2016. Patient accrual for the SJMB03 trial was done from Sept 9, 2003, until March 7, 2013 and for the SJYC07 trial was done from Dec 17, 2007, until March 31, 2017. The SJMB12 and I-HIT-MED trials are still accruing. The age limit for eligibility in the prospective studies was 5 years or younger (SJYC07), 3--21 years (SJMB03), and 3--39 years (SJMB12). Patients of all ages were eligible for the I-HIT-MED study. The retrospective cohort had no age limit for inclusion. Patients in the I-HIT-MED study were excluded if they were registered in another clinical trial for the same diagnosis (relapse is defined as a second diagnosis) or if a valid ethical committee approval was lacking.

Procedures {#cesec40}
----------

Whole-genome and whole-exome sequencing data for germline and tumour samples were generated at the German Cancer Research Centre (ICGC PedBrain; Heidelberg, Germany), Canada\'s Michael Smith Genome Sciences Centre (MAGIC; Vancouver, BC, Canada), Broad Institute of Massachusetts Institute of Technology and Harvard (Cambridge, MA, USA), and St Jude Children\'s Research Hospital (Pediatric Cancer Genome Project; Memphis, TN, USA).

To ensure standardisation of genomic data processing, we used the same uniform computational analysis workflows for all germline and tumour samples. We first unaligned samples that were provided to us as genomic alignment format (BAM) files. Subsequently, we aligned all samples using the same set of algorithms and the same human reference genome build (GRCH37, also known as hg19), based on data-processing standards defined by the [Pan-Cancer Analysis of Whole Genomes (PCAWG) project](https://dcc.icgc.org/pcawg){#interrefs60}.

For germline variant discovery, we used [freebayes](https://github.com/ekg/freebayes){#interrefs70} (version 1.1.0) in single-sample and paired-sample calling modes for discovery of single-nucleotide variants (SNVs), multiple nucleotide variants (MNVs), and insertions or deletions (indels) smaller than 50 base-pairs (bp; used parameters were --min-repeat-entropy 1, --report-genotype-likelihood-max, --alternate-fraction 0·2, and --no-partial-observations). Raw variant predictions were further filtered for quality (QUAL \>20, QUAL/AO \>2; where QUAL is −10 log~10~ Pr\[alternative allele is wrong\], and AO is alternative allele observation count), strand bias artifacts (SAF \>1, SAR \>1; where SAF is the number of alternate observations on the forward strand, and SAR is number of alternate observations on the reverse strand), read position artifacts (RPR \>1, RPL \>1; where RPR is the number of reads supporting the alternate balanced to the right \[3ʹ\] of the alternate allele, and RPL is the number of reads supporting the alternate balanced to the left \[5ʹ\] of the alternate allele), and normalised for consistent representation across patients with the variant analysis software [vt](https://genome.sph.umich.edu/wiki/Vt){#interrefs80} (version 0.5). We used [delly](https://github.com/dellytools/delly){#interrefs90} for germline genomic structural variant discovery with default settings for whole-genome sequencing samples and a custom read-depth-based copy-number variation (CNV)-calling pipeline for whole-exome sequencing samples. We based this custom pipeline on read quantification by [bedtools](https://github.com/arq5x/bedtools2){#interrefs100} in exome capture regions (MAQ \>30), followed by variance stabilising transformation of count data with the vst function from the DESeq2 R package (version 1.8.2), unsupervised estimation of hidden confounders using the R package PEER (30 hidden confounders), and copy-number segmentation based on standardised residuals using circular binary segmentation (R package DNAcopy, version 1.50, default settings). Raw CNV calls were filtered further for size (to include only those \>10 kb), minimum number of exons (\>2), and CNV signal intensity (\>4 SDs). Mosaic mutation discovery was based on freebayes and for donors with paired blood and tumour sequencing data. Any SNV, short indel, and MNV that was observed at low variant allele frequency in blood (3--15%) and high variant allele frequency in tumours (\>50%) was considered a putative mosaic mutation. We restricted the analysis to reads with mapping quality of more than 30 (−10 log~10~ Pr\[mapping position is wrong\]), base quality of more than 20 (−10 log~10~ Pr\[mapping position is wrong\]), and sites with more than 30 times sequencing coverage (ie, number of reads). We made no assumptions regarding the pathogenicity of putative mosaic mutations. We excluded any variant that was present in public genetic archives and discovered in germline genomes of other patients with medulloblastoma.

For classification of damaging germline mutations, germline variants were annotated with the Ensembl Variant Effect Predictor (VEP; r81). High-impact (ie, damaging) germline mutations were defined as frameshift, stop gain, start lost, canonical splice site, exon or gene deletions, known ([ClinVar](https://www.ncbi.nlm.nih.gov/clinvar/){#interrefs110}; accessed Feb 16, 2017) damaging non-canonical splice site variants, and somatic mosaic mutations (defined as mutations present in a subset of normal cells). Putative damaging germline mutations were removed if the estimated minor allele frequency in at least one continental population was more than 0·1%, which we judged on the basis of 53 105 sequenced individuals that were assigned to known (control) populations and without a cancer diagnosis from the [Exome Aggregation Consortium (ExAC)](http://exac.broadinstitute.org){#interrefs120} resource, the [1000 Genomes Project](http://www.internationalgenome.org){#interrefs130}, and the [National Heart, Lung, and Blood Institute GO Exome Sequencing Project](http://evs.gs.washington.edu/EVS/){#interrefs140}. Putative gain-of-function missense variants in *TP53* were further evaluated by use of information in the [International Agency for Research on Cancer TP53 database](http://p53.iarc.fr/){#interrefs150} and annotated as pathogenic if *TP53* mutations were classified as non-functional in experimental transcriptional activity assays. Finally, all germline mutations were excluded from the analysis if annotated as (likely) benign in ClinVar. Damaging germline structural variants were defined if they overlapped at least one exon and were absent in samples from the 1000 Genomes Project. We estimated the primary population ancestry (European, African, east Asian, south Asian, and Native American) for all patients with medulloblastoma with a supervised decomposition approach[@bib20] and ancestry-informative markers that are within ExAC-defined exome capture target regions.

Identification of somatic mutations (SNVs, small indels, and copy-number alterations) was pursued in a standardised manner across all samples (matched tumour or normal genome as well as exome pairs) with the German Cancer Research Center (known as DKFZ) and European Molecular Biology Laboratory cancer genome analysis workflow of the PCAWG consortium. Somatic SNVs and indels were further stringently filtered for germline contamination using information from [dbSNP](https://www.ncbi.nlm.nih.gov/projects/SNP/){#interrefs160} and the 1000 Genomes Project. Somatic structural variant discovery was pursued in a standardised way by use of an optimised version of delly. We used a high-stringency structural variant set by additionally filtering somatic structural variants detected in at least 1% of a set of 1105 germline samples from healthy individuals belonging to phase 1 of the 1000 Genomes Project, and by requiring absence of somatic structural variants in all medulloblastoma germline samples of this study. For inference of high-stringency structural variants, we additionally required at least four supporting read pairs[@bib21] with a minimum mapping quality of 20 (−10 log~10~ Pr\[mapping position is wrong\]) and restricted valid somatic structural variant sizes from 100 bp to 500 Mb.

We quantified previously defined somatic mutational signatures[@bib22] (termed 1, 3, 5, and 8) using tumour-specific somatic point-mutation spectra and [published signature probabilities](http://cancer.sanger.ac.uk/cosmic/signatures){#interrefs170}. These signatures comprise combinations of somatic mutations and represent consequences of mutagenic exposures and defective DNA repair pathways. Signatures 1 and 5 ("clock-like" signatures) are associated with ageing (a clock-like accumulation of mutations) and occur in normal, non-malignant cells,[@bib22] whereas signatures 3 and 8 are associated with homologous recombination repair deficiency (HRD) and have been reported in cancer tissues. We used these mutational signatures to further classify medulloblastoma genomes into two groups, a clock-like group (signatures 1 and 5) and a HRD-like group (signatures 3 and 8). Somatic mutation spectra were quantified with the R package SomaticSignatures (version 2.6) and decomposed into contributions of known mutational signatures based on the Lawson--Hanson algorithm for non-negative least squares (nnls version 1.1, R package). The quantification error (residual sum of squares) was correlated with the total somatic mutation burden (Spearman\'s *r*=0·74; p\<0·0001) and it was highest in tumours with fewer than 100 somatic SNVs. We have retained 375 whole-genome sequencing samples with more than 100 SNVs and low quantification error (\<0·02) for signature analysis. Medulloblastomas were classified as homologous recombination repair deficient if most (\>50%) somatic SNVs were assigned to mutational signatures 3 or 8.

To assess the burden of rare germline SNVs and indels in cancer predisposition genes, we performed case--control association testing in a subgroup-specific manner as well as across all subgroups based on a collection of 110 autosomal cancer predisposition genes[@bib8], [@bib23] ([appendix p 2](#sec1){ref-type="sec"}). All patients with medulloblastoma in our retrospective discovery cohort were eligible for rare variant burden analysis. We used 53 105 sequenced individuals without a known cancer diagnosis from ExAC (release 0.3) as controls. Age and sex were not matched between cases and controls because of missing information from ExAC. To ensure comparability with variants found in patients with medulloblastoma, ExAC germline mutations were normalised with vt normalize, annotated with VEP (r81), and filtered for sites that passed quality controls, as defined by ExAC. Moreover, we excluded any germline mutations that were present outside ExAC-defined target regions to reduce any possible advantages derived from improved variant calling in whole-genome sequences (eg, exons not being covered in ExAC). Furthermore, we also did not include pathogenic structural variants in our rare variant burden analysis. We assumed equal effect sizes for frameshift, nonsense, splice site, and gain-of-function missense variants, as well as for variants located at any position along a gene. The total number of damaging (*a*) and wild-type (*A*) alleles were counted for each gene in cases and controls, recorded in a 2 × 2 contingency table, and evaluated for statistical independence of rows (case and control) and columns (allele *a* and allele *A*) with Fisher\'s exact test (to 1 df) implemented in R version 3.4 using the fisher.exact function. Unadjusted p values were recorded for each gene and adjusted for multiple testing correction with the Bonferroni method. We only considered genes for which more than four pathogenic alleles were observed in cases and controls. Allelic relative risks were estimated by the odds ratio (OR), which describes the association between medulloblastoma and damaging alleles by comparing the odds of medulloblastoma in an individual carrying a wild-type allele to the odds of medulloblastoma in an individual carrying one damaging allele. We assumed that the penetrance of monoallelic germline mutations was lower than that of biallelic germline mutations (ie, homozygous and compound heterozygous mutations).

We assessed secondary somatic gene hits in tumours on three levels: point mutations, loss-of-heterozygosity, and allele-specific gene expression. Somatic point mutations were assumed to occur in trans (ie, on a different haplotype). Loss of heterozygosity was quantified by use of genotyping germline alleles in available tumour genomes or exomes with freebayes and requiring a minimum coverage of ten reads, minimum base quality of 10 (−10 log~10~ Pr\[base is wrong\]), and minimum mapping quality of 10 (−10 log~10~ Pr\[mapping position is wrong\]). Loss of heterozygosity was inferred if the variant allele frequency was above 80% in tumour sequences. Allele-specific gene expression was quantified at heterozygous SNVs and indels and mRNA sequencing data by use of freebayes (minimum mapping quality of 10 \[−10 log~10~ Pr(mapping position is wrong)\] and minimum base quality of 10 \[−10 log~10~ Pr(base is wrong)\]) and was predicted on the basis of binomial tests, an expected ratio of 0·5, and p values lower than 0·05. When possible, multiple sites within the same gene were phased with paired-end RNA sequencing data and individual sites were merged to calculate haplotype-specific expression ratios.

We investigated chromothripsis using previously established criteria.[@bib24] These criteria distinguish chromothripsis from DNA rearrangements occurring in a stepwise fashion. First, we analysed breakpoint clustering in the entire genome based on high-confidence somatic structural variant calls and did statistical analysis for non-randomness of breakpoint distributions, under the assumption of an exponential distribution (null hypothesis). Breakpoint clustering generates highly clustered DNA breaks that might be followed by long tracts of intact DNA segments. For each sample and chromosome, a Kolmogorov--Smirnov test was used to test against the null hypothesis. Then we assessed the randomness of DNA rearrangements using a multinomial test (implemented in the R package EMT) for chromosomes with putative chromothripsis patterns. For chromosomes undergoing chromothripsis, the shattered fragments were randomly stitched together according to the original chromothripsis model. This model implies that for each DNA break, the orientation of the two joined DNA fragment ends will be random. We tested the observed distribution of rearrangement joins (tail-to-head, head-to-tail, head-to-head, and tail-to-tail) against a background model of occurrence with equal probability (ie, a probability of 0·25 for each rearrangement).

Molecular classification of medulloblastomas into consensus subgroups[@bib9] (MB~WNT~, MB~SHH~, MB~Group3~, and MB~Group4~) was determined by DNA methylation profiling.[@bib25]

Statistical analysis {#cesec50}
--------------------

No formal sample size and power calculations were done in this study, since we made use of all germline genomes and exomes available to us. Samples with missing data were excluded from specific analysis. We used Fisher\'s exact and χ^2^ tests for associations with binary and categorical variables, and Mann-Whitney *U* and Kruskal-Wallis tests for associations with quantitative values. Survival analysis was based on the Kaplan-Meier estimator and log-rank tests using the R package suvival (version 2.41), and survival curves were visualised using the R package survminer (version 0.4.2). Overall survival and progression-free survival were based on definitions consistent with how they were evaluated within each respective patient cohort from each prospective trial: SJMB03, SJMB12, and SJYC07. The prospective observational patient registry I-HIT-MED had no formal endpoints and so no statistical analyses were defined. Detailed outcome measures for all four studies are available on [ClinicalTrials.gov](http://ClinicalTrials.gov){#interrefs180}. One-sided binomial tests were used for replication analysis with the alternative hypothesis defined as a lower probability of observing germline mutations in the replication cohort.

Role of the funding source {#cesec60}
--------------------------

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data and had the final responsibility to submit for publication.

Results {#cesec70}
=======

We analysed germline genome-sequencing and exome-sequencing data ([appendix pp 8--9](#sec1){ref-type="sec"}) from 1022 patients with medulloblastoma, of whom 673 were in the retrospective discovery cohort and 349 were in the prospective clinical study cohort ([figure 1A](#fig1){ref-type="fig"}, [appendix p 3](#sec1){ref-type="sec"}). Patient-matched tumour genomes were sequenced for 800 samples from both cohorts (n=451 retrospective and n=349 prospective) from whole-genome sequencing (n=397) and whole-exome sequencing (n=403; [figure 1A](#fig1){ref-type="fig"}). Molecular classification of medulloblastomas into subgroups was done for 844 patients (n=496 retrospective cohort and n=348 prospective cohort). SNVs, MNVs, small (\<30 bp) indels, and large structural variants were predicted across 110 paediatric-onset and adult-onset cancer predisposition genes[@bib8], [@bib23] and classified as pathogenic based on stringent criteria.Figure 1Discovery and replication of medulloblastoma predisposition genes(A) Study design and patient characteristics. (B) Rare variant burden analysis based on 673 patients with medulloblastoma and 53 105 controls from the Exome Aggregation Consortium. Diagnosis of medulloblastoma was the outcome variable. Proportion of patients with a genetic predisposition in our (C) retrospective cohort and (D) prospective cohort. (D) p values indicate statistical differences in the proportion of germline mutation carriers in the retrospective compared with prospective cohort. Infant=age 3 years or younger. Child=age 4--17 years. Adult=age 18 years or older. RR=relative risk. \*p\<0·001. †p\<0·01. ‡p\<0·05. §Patients with damaging germline mutations in *APC, PTCH1, SUFU, TP53, PALB2*, and *BRCA2*.

We identified damaging germline mutations in 76 (11%) of 673 patients in our retrospective cohort and across 32 genes ([appendix pp 10--12](#sec1){ref-type="sec"}). Most damaging germline mutations have been previously described in the literature (in 55 \[71%\] of 77 mutations) and already classified as (likely) pathogenic (42 \[55%\] of 77) in public archives (ClinVar, LOVD; [appendix pp 10--12](#sec1){ref-type="sec"}). Discovery of consensus medulloblastoma predisposition genes was based on rare variant burden analysis using 673 patients with medulloblastoma and 53 105 ExAC controls. In total, six genes showed a significant excess of damaging germline mutations for patients with medulloblastoma---namely, *APC, BRCA2, PALB2, PTCH1, SUFU*, and *TP53* (adjusted p value for multiple testing \<0·05; [figure 1B](#fig1){ref-type="fig"}, [appendix p 4](#sec1){ref-type="sec"}). Restricting the analysis to patients and controls with European population ancestry revealed no additional candidate medulloblastoma predisposition genes ([appendix p 4](#sec1){ref-type="sec"}). Moreover, we did not identify patients with biallelic germline mutations in mismatch repair genes (ie, *MSH2, MSH6, MLH1*, and *PMS2*). However, a single patient in our discovery cohort harboured a heterozygous germline mutation in *MSH6* ([appendix pp 10--12](#sec1){ref-type="sec"}).

The overall prevalence of genetic predisposition based on these six genes in the retrospective discovery cohort was 6% (40/673), with a highest prevalence of 20% (28/141) in patients in the MB~SHH~ subgroup ([figure 1C](#fig1){ref-type="fig"}). Replication of these estimates was based on 349 patients who were enrolled in the prospective clinical studies. Key patient characteristics, such as sex, age at diagnosis, and molecular tumour subgroups, were similar between both cohorts (p~sex~=0·68, p~age~=0·17, p~subgroup~=0·12; [figure 1A](#fig1){ref-type="fig"}). The overall prevalence of genetic predisposition in our prospective cohort (17 \[5%\] of 349) was consistent with estimates from our retrospective cohort (p=0·24; [figure 1D](#fig1){ref-type="fig"}, [appendix pp 10--12](#sec1){ref-type="sec"}). We further replicated the high prevalence of genetic predisposition in patients in the MB~SHH~ subgroup ([figure 1D](#fig1){ref-type="fig"}). Notably, patients in the MB~WNT~ subgroup also had an increased prevalence of germline predisposition in both the discovery and replication cohort, albeit more modest than for patients in the MB~SHH~ subgroup ([figure 1C, D](#fig1){ref-type="fig"}).

We closely analysed key demographic, clinical, and molecular characteristics of patients with a genetic predisposition in these six genes. Most patients with available subgroup information developed MB~SHH~ (41 \[76%\] of 54; [figure 2A](#fig2){ref-type="fig"}) and age at diagnosis also differed significantly between patients with germline mutations in medulloblastoma predisposition genes (p\<0·0001; [figure 2B](#fig2){ref-type="fig"}). Patients with germline *SUFU* or *PTCH1* mutations were typically diagnosed as infants at a median age of 2·0 years (IQR 1·3--2·3), whereas patients with *APC* or *TP53* mutations were diagnosed as children at a median age of 9·8 years (IQR 8·0--11). Analysis of histological subtypes in relation to genetic predisposition is presented in the [appendix (p 2)](#sec1){ref-type="sec"}. Clinical signs of a genetic predisposition were noted in 16 (41%) of 39 patients and familial history of cancer in 17 (46%) of 37 patients, and both were different between patients with germline mutations in medulloblastoma predisposition genes (p=0·017 and p=0·046, respectively; [figure 2C, 2D](#fig2){ref-type="fig"}). For example, only one (9%) of all 11 *PTCH1* and *SUFU* mutation carriers with available medical records had a family history of cancer; however, eight (67%) of 12 patients with available medical records had clinical symptoms consistent with Gorlin\'s syndrome (eg, macrocephaly, jaw cysts, and frontal bossing; [appendix pp 10--12](#sec1){ref-type="sec"}). By contrast, all four *APC* mutation carriers with available medical records had a familial history of familial adenomatous polyposis and associated cancers (eg, adrenocortical carcinoma). Of note, additional malignancies were observed in six (12%) of 50 patients with medulloblastoma and all were restricted to patients with germline *APC* (n=3) or *TP53* (n=3) mutations ([appendix pp 10--12](#sec1){ref-type="sec"}).Figure 2Clinical characteristics of patients with a genetic predisposition(A) Molecular tumour subgroups. (B) Age at diagnosis. (C) Family history of cancer. (D) Clinical signs of a genetic predisposition. p values indicate whether there is a difference between patients with different types of genetic predisposition. \*Patients with compound heterozygous germline *BRCA2* mutations. †Data are median (IQR). Circle sizes indicate the proportion of patients with a genetic predisposition.

At a median follow-up of 48 months (IQR 28--78), 5-year progression-free survival for 49 patients with a genetic predisposition who were evaluable for this outcome was 52% (95% CI 40--69). 5-year overall survival in 47 evaluable patients with a genetic predisposition was 65% (95% CI 52--81). Progression-free survival (log-rank p=0·0056) and overall survival (log-rank p=0·00032) differed significantly across patients with germline mutations in different medulloblastoma predisposition genes ([figure 3](#fig3){ref-type="fig"}).Figure 3Kaplan-Meier curves for survival outcomes of patients with a genetic predisposition(A) Progression-free survival. (B) Overall survival. Log-rank p values indicate differences across all patient groups.

Germline *APC* mutations were found in seven (1%) of all 1022 patients with medulloblastoma and included one infant, five children, and one adult patient. Two of these seven patients harboured partial or full gene deletions ([appendix p 5](#sec1){ref-type="sec"}) and the remaining five patients had frameshift and nonsense mutations between codons 554 and 1113, a region associated with classical familial adenomatous polyposis phenotypes. Molecular subgroup information was available for six cases and showed that all five children developed MB~WNT~. One infant developed MB~SHH~ ([appendix p 1](#sec1){ref-type="sec"}). All five WNT-driven medulloblastomas lost the wild-type *APC* allele and the SHH-driven medulloblastoma showed retention of the wild-type allele ([figure 4A](#fig4){ref-type="fig"}). Furthermore, germline *APC* mutations in MB~WNT~ patients were mutually exclusive with somatic *CTNNB1* exon 3 mutations (p\<0·0001), the primary[@bib26] somatic driver event in MB~WNT~ ([figure 4B](#fig4){ref-type="fig"}). Overall, germline *APC* mutations were identified in five (71%) of seven *CTNNB1*-wild-type MB~WNT~ cases and, together with somatic *CTNNB1* mutations, explained 97% (64/66) of all WNT-driven medulloblastomas. By contrast, monosomy 6---a frequent somatic chromosome aberration in MB~WNT~ (in 55 \[83%\] of 66 cases)---was not mutually exclusive with germline *APC* mutation status (p=0·19); although we observed two patients with *APC* mutations and balanced chromosome 6 ([figure 4B](#fig4){ref-type="fig"}). We recorded no difference in age at diagnosis between patients with germline *APC* mutations and somatic *CTNNB1* mutations (p=0·92; [figure 4B](#fig4){ref-type="fig"}). Overall and progression-free survival for patients with *APC*-MB~WNT~ was 100% (95% CI 100--100).Figure 4Molecular medulloblastoma characteristics for patients with a genetic predisposition(A) Patterns of somatic inactivation of wild-type alleles for all patients with a germline mutation in one of the consensus medulloblastoma predisposition genes. Circle sizes indicate the proportion of patients with a genetic predisposition. (B) Somatic driver events in patients with medulloblastoma in the WNT subgroup (top panel) and age at diagnosis for all patients with germline *APC* mutations and patients in the WNT subgroup with somatic *CTNNB1* mutations (bottom panel). (C) Association between germline *PALB2* (n=5) and *BRCA2* (n=7) mutation status and somatic mutational signatures 1, 3, 5, and 8. EXP=allele-specific gene expression. MUT=somatic inactivation via single nucleotide variation, insertion, or deletion. LOH=loss of heterozygosity. ND=no somatic alteration detected. NS=not significant. HRD=homologous recombination repair deficiency. \*Present study and Hamilton and colleagues.[@bib5] †p\<0·001. ‡p\<0·01. §p\<0·05.

Germline *TP53* mutations were found in 14 (1%) of all 1022 patients with medulloblastoma and were only present in patients with MB~SHH~ (13/13; data missing for one patient). Notably, germline *TP53* mutations were identified in 13 (8%) of 170 paediatric MB~SHH~ patients and 13 (20%) of 63 children aged between 5 years and 16 years with MB~SHH~. Only five (4%) of 11 patients with germline *TP53* mutations had a family history of cancer ([figure 2B](#fig2){ref-type="fig"}). Most germline *TP53* mutations (13/14) clustered within the DNA-binding domain ([appendix p 6](#sec1){ref-type="sec"}) and somatic inactivation of the wild-type *TP53* allele was detected in all 13 available medulloblastoma genomes via loss of heterozygosity ([figure 4A](#fig4){ref-type="fig"}). All eight whole-genome-sequenced *TP53*-deficient MB~SHH~ exhibited complex somatic genomic rearrangements consistent with chromothripsis[@bib21] and accounted for eight (57%) of all 14 chromothripsis events in the MB~SHH~ subgroup. The remaining six patients with chromothripsis-positive MB~SHH~ harboured somatic *TP53* mutations. 5-year overall survival for patients with germline *TP53* mutations was 27% (95% CI 10--72; [figure 3](#fig3){ref-type="fig"}).

Germline *SUFU* and *PTCH1* mutations were detected in 20 (2%) of all 1022 patients with medulloblastoma, exclusively in the MB~SHH~ subgroup (19/19; data missing for one patient), and accounted for 11% (18/170) of all paediatric patients with MB~SHH~ and 21% (17/80) of all infant patients with MB~SHH~. We observed somatic loss of the *SUFU* or *PTCH1* wild-type allele in all (n=18) sequenced MB~SHH~ that were diagnosed in patients with germline *SUFU* or *PTCH1* mutations. Most (15/18) *SUFU*-deficient or *PTCH1*-deficient MB~SHH~ lost the wild-type allele via loss of heterozygosity ([figure 4A](#fig4){ref-type="fig"}). Only six of 20 germline *SUFU* and *PTCH1* mutations have been previously described in the literature ([appendix pp 10--12](#sec1){ref-type="sec"}), suggesting either appreciable amounts of de-novo mutagenesis or poor reporting to public archives. In support of the de-novo mutagenesis theory, a de-novo germline *PTCH1* mutation was observed in a patient with MB~SHH~ from our retrospective cohort, for whom whole-exome sequences were also available for both parents. We also identified putative protein-truncating mosaic *PTCH1* mutations in three patients with MB~SHH~ (in whom variant allele frequency ranged from 4·7% to 6·7% in the blood). Clinical information was available for one patient with a mosaic *PTCH1* mutation, which showed that the patient was clinically diagnosed with Gorlin\'s syndrome and the patient had no family history of cancer and no family history of Gorlin\'s syndrome. Moreover, comparison of clinical outcomes between patients with germline mutations in *SUFU* and *PTCH1* showed no differences in progression-free survival (p=0·50, 16 patients with germline mutations) and overall survival (p=0·91, 17 patients with germline mutations). Notably, patients with germline mutations in either *SUFU* or *PTCH1* had a better overall survival than progression-free survival (combined 5-year progression-free survival 56% for *SUFU* and *PTCH1* mutations, 95% CI 37--87; combined 5-year overall survival 85%, 95% CI 67--100; [figure 3](#fig3){ref-type="fig"}).

Germline *BRCA2* mutations were present in 11 (1%) of all 1022 patients with medulloblastoma and included ten paediatric patients and one adult (survival data not available for all patients with these mutations). The median age at diagnosis was 5·7 years (IQR 3·0--8·3). Most of these mutations (16 \[89%\] of 18) were previously classified as pathogenic according to ClinVar ([appendix pp 10--12](#sec1){ref-type="sec"}). We observed compound heterozygosity at *BRCA2* in four (36%) of 11 patients. Clinical signs of a genetic predisposition or family history of cancer were noted in all four compound heterozygous patients and in four (80%) of five heterozygous patients with available medical records. Patients with compound heterozygous mutations at *BRCA2* developed exclusively MB~SHH~ (p=0·0060 when compared with any other subgroup; [figure 2A](#fig2){ref-type="fig"}) and exhibited worse progression-free survival (p=0·025) and overall survival (p=0·022) relative to patients with heterozygous germline *BRCA2* mutations ([figure 3](#fig3){ref-type="fig"}). When compared with 53 105 controls, the burden of rare germline mutations in *BRCA2* was associated with increased risk of MB~SHH~ (relative risk \[RR\] 13·8 \[5·4--29·4\]; p\<0·0001) and MB~Group3/4~ (RR 4·2 \[1·4--10·1\]; p=0·0077). Overall and progression-free survival of heterozygous germline *BRCA2* mutation carriers was 100% (95% CI 100--100) and none developed secondary malignancies. Analysis of medulloblastoma genomes revealed that all seven heterozygous *BRCA2* mutation carriers retained the wild-type *BRCA2* allele. Additional details about family history of cancer, parental genetic testing, and somatic mutation profiles in heterozygous and compound heterozygous *BRCA2* mutation carriers are provided in the [appendix (p 1)](#sec1){ref-type="sec"}.

Germline *PALB2* mutations were found in five (\<1%) of all 1022 patients with medulloblastoma. We identified three patients with MB~SHH~, one patient with MB~Group3~ and one patient with MB~Group4~. All five damaging germline mutations were heterozygous in patients affected with medulloblastoma and were previously reported in familial pancreatic and breast cancer studies.[@bib27] All five germline mutations were classified as pathogenic according to ClinVar ([appendix pp 10--12](#sec1){ref-type="sec"}). Although heterozygous *PALB2* mutations are known[@bib8] to increase the risk of adult-onset cancers (eg, breast cancer), predisposition to paediatric malignancies has so far only been described in the context of Fanconi anaemia.[@bib28] We excluded the predisposition to Fanconi anaemia in all five cases because of an absence of additional rare germline mutations (including protein-truncating variants, missense mutations, and inframe indels). Furthermore, clinical signs of a genetic disorder were absent in both paediatric cases with available medical records ([figure 2D](#fig2){ref-type="fig"}). Analysis of medulloblastoma genomes revealed somatic inactivation of the wild-type *PALB2* allele in all three paediatric cases and retention of heterozygosity in both adult cases ([figure 4A](#fig4){ref-type="fig"}). 5-year overall and progression-free survival for patients with germline *PALB2* mutations was 75% (95% CI 43--100). Additional details about family history of cancer, parental genetic testing, and somatic mutation profiles available for one affected patient are presented in the [appendix (p 1)](#sec1){ref-type="sec"}.

Since the clinical relevance of heterozygous germline mutations in *PALB2* and *BRCA2* is uncertain, we aimed to corroborate our findings through investigation of somatic mutation patterns (mutational signatures) in medulloblastoma genomes. Quantification of four previously implicated mutational signatures (signatures 1, 3, 5, and 8) across 375 medulloblastoma genomes showed a significant association between both HRD signatures (signatures 3 and 8) and germline *BRCA2* and *PALB2* mutation status ([figure 4C](#fig4){ref-type="fig"}, [appendix p 7](#sec1){ref-type="sec"}). Moreover, although the overall prevalence of an HRD-like mutation spectrum was modest in medulloblastoma (58 \[15%\] of 375), it was enriched in *BRCA2*-deficient and *PALB2*-deficient tumours as compared with tumours with other genetic mutations (OR 19·0 \[95% CI 4·5--113\], p\<0·0001). In total, nine (75%) of 12 *BRCA2*-deficient and *PALB2*-deficient tumours showed evidence for an HRD-like mutation spectrum. Strikingly, eight (89%) of nine patients with MB~SHH~ and an HRD-like mutation spectrum harboured germline mutations in consensus medulloblastoma predisposition genes (*BRCA2* n=4, *PALB2* n=2, and *TP53* n=2), suggesting that HRD might serve as a biomarker for genetic predisposition in this patient group. We also observed five patients in the MB~WNT~ subgroup with an HRD-like mutation spectrum and noticed that four (89%) of five cases were diagnosed as adults (p=0·0003 for paediatric *vs* adult cases). The only paediatric patient in the MB~WNT~ subgroup with an HRD-like mutation spectrum harboured a pathogenic heterozygous germline mutation in *ATM* along with somatic inactivation of the wild-type *ATM* allele ([appendix pp 10--12](#sec1){ref-type="sec"}). Finally, we also identified heterozygous germline mutations in *FANCA* (n=1) and *FANCQ* (n=1) in patients with MB~Group3~ and MB~Group4~, respectively, and an HRD-like mutation spectrum. Taken together, these results corroborate our genetic findings and indicate that genetic alteration of homologous recombination genes is associated with an HRD-like mutation spectrum in medulloblastoma.

Discussion {#cesec80}
==========

To the best of our knowledge, this study is the largest so far on genetic predisposition in a single paediatric brain tumour entity. Our rare variant burden analyses revealed that genetic predisposition has a major role in the cause of medulloblastoma after accounting for molecular subgroups, with a high prevalence in MB~WNT~ and MB~SHH~ patient subgroups. Moreover, we identified that less than half of all germline cases were suspected based on medical records and that patients with genetic predispositions exhibit distinct clinical outcomes. Our data show the urgent need to establish genetic counselling and genetic testing as a standard-of-care procedure in patients with MB~WNT~ and MB~SHH~. We therefore provide clinical screening guidelines based on routinely acquired patient and tumour characteristics ([figure 5](#fig5){ref-type="fig"}). Recommendations for surveillance and clinical management of individual childhood cancer predisposition syndromes have been summarised in a series of articles[@bib29] from the American Association for Cancer Research Childhood Cancer Predisposition Workshop. Our study complements these recommendations by providing additional diagnostic criteria based on clinical and molecular characteristics.Figure 5Proposed clinical guidelines for genetic counselling and testing in medulloblastoma based on clinical and molecular tumour characteristics

Here, we identified heterozygous germline *APC* mutations in 6--8% of patients in the MB~WNT~ molecular subgroup and showed that genetic cases were indistinguishable from sporadic cases based on age at diagnosis. Importantly, all patients with *APC*-deficient MB~WNT~ did not have the hallmark somatic driver event of MB~WNT~---namely, somatic missense mutations in *CTNNB1* (the gene encoding β-catenin). Overall, germline *APC* and somatic *CTNNB1* mutations accounted for nearly all (97%) MB~WNT~ diagnoses. We therefore recommend genetic counselling only for germline *APC* mutations in patients with MB~WNT~. In our series, patients with MB~WNT~ and germline *APC* mutations showed favourable clinical outcomes, which mirrors the favourable outcome for patients with MB~WNT~ with nuclear accumulation of β-catenin.[@bib30] Nevertheless, several patients with germline *APC* mutations had an additional malignancy, which emphasises the need to provide genetic counselling for patients with MB~WNT~ in the future, irrespective of clinical outcomes. Notably, we also observed a patient with atypical *APC* who was diagnosed during infancy with MB~SHH~ and retained the wild-type *APC* allele. Additional studies will be needed to assess whether or not germline *APC* mutations are a genetic risk factor for MB~SHH~.

Given the particularly high prevalence of damaging germline mutations in patients with MB~SHH~, we recommend that all patients with MB~SHH~ should be counselled for genetic testing. We recommend ordering of these tests by age at diagnosis and molecular phenotypes (eg, chromothripsis or HRD signatures). Patients younger than 3 years of age should initially be tested for germline mutations in *SUFU* and *PTCH1* (especially in view of the high prevalence of *SUFU* mutations in infant patients with MB~SHH~ in our study, which is consistent with previous reports[@bib31]), and children older than 3 years for germline *TP53* mutations. By contrast, germline mutations in *PALB2* and *BRCA2* showed no strict associations with age at diagnosis (observed in infants, children, and adults). We thus recommend that patients with MB~SHH~ should be screened for germline mutations in *PALB2* and *BRCA2* following a negative test result for the aforementioned genes. We further observed germline *PALB2* and *BRCA2* mutations in 1--2% of patients with MB~Group3/4~. Based on these findings we recommend conservative ordering of genetic tests in these patient groups (eg, those with familial history of *BRCA*-associated cancers or if mutational signatures are suggestive of HR deficiency---specifically signatures 3 and 8, the latter of which has previously been reported to be associated with breast cancer).[@bib32]

*G*enetic counselling and testing for germline *PALB2* and *BRCA2* mutations in paediatric patients has so far been pursued only in case of suspected Fanconi anaemia. By use of integrative genomic analyses, we showed that heterozygous mutations in *BRCA2* and *PALB2* are associated with an increased risk of medulloblastoma and of HR-deficient tumours. All identified heterozygous germline mutations are rare in the general population (minor allele frequency \<0·01%) and were classified in most patients as (likely) pathogenic in ClinVar. Magnusson and colleagues[@bib33] reported that families with germline mutations in *BRCA2* had an increased prevalence of childhood tumours compared with population-based control families. Medulloblastoma genomes from patients with heterozygous germline mutations in *BRCA2* and *PALB2* described in our study show strong signs of HRD. Many studies have sought to elucidate the mechanisms of genomic instability in heterozygous *BRCA2* and *PALB2* mutation carriers. For example, it was shown that cells from heterozygous *PALB2* mutation carriers exhibited an aberrant DNA replication stress response and increased amounts of spontaneous genomic instability,[@bib34] and analysis of double-strand break repair outcomes[@bib35] revealed a shift towards error-prone DNA repair pathways. Furthermore, one study[@bib36] presented evidence showing that naturally occurring concentrations of formaldehyde, a product of cellular metabolism, can selectively deplete BRCA2 via proteasomal degradation and induce genomic instability. Although wild-type cells retained adequate protein concentrations in that study, cells heterozygous for truncating *BRCA2* mutations showed enhanced susceptibility to formaldehyde-induced genomic instability. Future research is needed to understand whether and to what extent *BRCA2* and *PALB2*-deficient medulloblastomas might be sensitive to aldehyde-induced DNA damage. Moreover, consequent identification of paediatric patients with heterozygous germline mutations in *PALB2* and *BRCA2* will be valuable to further evaluate whether HR-deficient tumours show a particularly favourable response to standard platinum-based chemotherapy and whether they might benefit from combination therapies with *PARP* inhibitors.

Germline mutations in *TP53* accounted for the highest proportion of genetic cases among paediatric patients in the MB~SHH~ subgroup. This patient group showed especially poor clinical outcomes as well as secondary malignancies. This finding underscores the need for a dedicated treatment protocol, which is being prepared by the International Society of Paediatric Oncology PNET 5 Medulloblastoma study group and by an international registry for this high-risk patient group.[@bib37] Additionally, clinical surveillance of germline *TP53* mutation carriers has been shown to result in earlier detection of tumours and therefore improved long-term survival.[@bib38]

We also observed rare and damaging germline mutations with potential clinical relevance in additional genes based on loss of heterozygosity analysis and somatic mutation patterns (eg, *ATM* and *PTEN*). The molecular and clinical evidence reported in this study was, however, not fully conclusive for these additional genes. Long-term follow-up studies and more detailed molecular analysis will be necessary to provide unambiguous recommendations for routine genetic screening of these genes. Of note, we did not identify patients with biallelic germline mutations in mismatch repair genes (*MSH2, MSH6, MLH1*, and *PMS2*). A single patient harboured a heterozygous germline *MSH6* mutation in our discovery cohort; however, the meaning of this observation remains uncertain owing to the absence of tumour material for molecular analyses.

Our study does have some limitations. Because of the multiple (and in part heterogeneous) cohorts used in our study, familial history of cancer could not be obtained in a standardised form for all patients carrying a genetic predisposition. Furthermore, we did not make any effort to pursue retrospective collection of clinical information from patients without a detected genetic predisposition. Larger cohort sizes in further studies will be necessary to assess the impact of germline mutations on clinical outcomes within molecular subgroups as well as relative to patients who develop sporadic medulloblastoma due to somatic mutations in the same set of genes (eg, *PTCH1, SUFU*, and *TP53*). These larger molecular cohorts will further enable pinpointing of shared somatic driver events in patients with a genetic predisposition. Furthermore, we note that our rare variant burden analysis against ExAC was restricted to regions covered by whole-exome sequencing, was restricted to genes previously involved in cancer predisposition, and excluded pathogenic germline structural variants. Although these steps aimed to reduce potential biases from analysing heterogeneous sequencing cohorts, we cannot rule out that particular classes of germline variation might have been under-represented. Finally, it is also possible that additional genes are involved in medulloblastoma predisposition, which were not previously associated with hereditary cancer syndromes.
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